Molderings G J, Göthert M
Institut für Pharmakologie und Toxikologie, Rheinischen Friedrich-Wilhelms-Universität Bonn, Germany.
Fundam Clin Pharmacol. 1998;12(4):388-97. doi: 10.1111/j.1472-8206.1998.tb00962.x.
In rat vena cava and aorta preincubated with [3H]noradrenaline the involvement of imidazoline receptors in modulation of [3H]noradrenaline release from sympathetic nerves was investigated. In the vena cava, the guanidine 1,3-di(2-tolyl)guanidine (DTG) inhibited the electrically evoked [3H]noradrenaline release; the inhibitory effect was more pronounced in the presence than in the absence of the alpha 2-adrenoceptor antagonist rauwolscine. The concentration-response curves of BDF 6143 [4-chloro-2-(2-imidazolin-2-ylamino)-isoindoline], and idazoxan for their facilitatory effect on electrically evoked [3H]noradrenaline release was bell-shaped; in the presence of rauwolscine, BDF 6143 inhibited the evoked [3H]noradrenaline release, whereas idazoxan did not. After blockade of alpha 2-autoreceptors by rauwolscine, the electrically evoked [3H]noradrenaline release from vena cava was inhibited not only by DTG and BDF 6143 but also by aganodine, clonidine and cirazoline; the rank order of potency of most of the drugs was similar to that found at the presynaptic imidazoline receptors in the rabbit aorta and pulmonary artery as well as in human atrial appendages. In the presence of rauwolscine, clonidine-induced inhibition of electrically evoked [3H]noradrenaline release was counteracted by 1 microM of the selective CB1 receptor antagonist SR141716A (N-[piperidin-1-yl]-5-[4-chlorophenyl]-1-[2,4-dichlorophenyl] -4-methyl-1H-pyrazole-3-carboxamide). In the aorta, BDF 6143 and cirazoline did not modify [3H]noradrenaline release in the absence of alpha 2-adrenoceptor blockade; in the presence of rauwolscine, the electrically evoked [3H]noradrenaline release from aorta was inhibited by BDF 6143, cirazoline, aganodine and clonidine with a rank order of potency similar to that in the vena cava. SR141716A 1 microM antagonized the inhibitory effect of BDF 6143 and clonidine (in the presence of rauwolscine). In conclusion, noradrenaline release in rat vena cava and aorta is inhibited via presynaptic imidazoline receptors which appear to be related to those previously characterized in rabbit and human cardiovascular tissue.
在用[3H]去甲肾上腺素预孵育的大鼠腔静脉和主动脉中,研究了咪唑啉受体在调节交感神经释放[3H]去甲肾上腺素中的作用。在腔静脉中,胍1,3 - 二(2 - 甲苯基)胍(DTG)抑制电诱发的[3H]去甲肾上腺素释放;在存在α2 - 肾上腺素能受体拮抗剂萝芙木碱的情况下,这种抑制作用比不存在时更明显。BDF 6143 [4 - 氯 - 2 - (2 - 咪唑啉 - 2 - 基氨基) - 异吲哚啉]和咪唑克生对电诱发的[3H]去甲肾上腺素释放的促进作用的浓度 - 反应曲线呈钟形;在存在萝芙木碱的情况下,BDF 6143抑制诱发的[3H]去甲肾上腺素释放,而咪唑克生则没有。在用萝芙木碱阻断α2 - 自身受体后,腔静脉电诱发的[3H]去甲肾上腺素释放不仅受到DTG和BDF 6143的抑制,还受到阿加诺定、可乐定和西拉唑啉的抑制;大多数药物的效价顺序与在兔主动脉和肺动脉以及人心房附件的突触前咪唑啉受体上发现的相似。在存在萝芙木碱的情况下,1 microM的选择性CB1受体拮抗剂SR141716A (N - [哌啶 - 1 - 基] - 5 - [4 - 氯苯基] - 1 - [2,4 - 二氯苯基] - 4 - 甲基 - 1H - 吡唑 - 3 - 甲酰胺)可抵消可乐定诱导的对电诱发的[3H]去甲肾上腺素释放的抑制作用。在主动脉中,在不存在α2 - 肾上腺素能受体阻断的情况下,BDF 6143和西拉唑啉不改变[3H]去甲肾上腺素释放;在存在萝芙木碱的情况下,主动脉电诱发的[3H]去甲肾上腺素释放受到BDF 6143、西拉唑啉、阿加诺定和可乐定的抑制,其效价顺序与腔静脉中的相似。1 microM的SR141716A拮抗BDF 6143和可乐定(在存在萝芙木碱的情况下)的抑制作用。总之,大鼠腔静脉和主动脉中的去甲肾上腺素释放通过突触前咪唑啉受体受到抑制,这些受体似乎与先前在兔和人类心血管组织中鉴定的受体有关。